ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0216

Can Immune Checkpoint Inhibitors Safely Combat Cancer in Patients with Rheumatoid Arthritis?

Betul Ibis and Furkan Bahar, Mount Auburn Hospital/Harvard Medical School, Watertown, MA

Meeting: ACR Convergence 2024

Keywords: rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Health Services Research – ACR/ARP Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: During the past decade, antibody-based immunotherapies (including anti-PD1, anti-PD-L1, and anti-CTLA4) have revolutionized cancer treatment by enhancing the body’s immune response against tumors. However, it is not possible to specifically target the inhibition signals in the tumor microenvironment (TME) without affecting other areas. Blocking these inhibitory checkpoints can cause autoimmune-like phenomena called immune-related side effects  in multiple organ systems due to global immune activation. Therefore, the use of ICI in patients with pre-existing autoimmune diseases (PADs) has been hampered by the potential for immune-related adverse events (irAEs). Rheumatic irAEs encompass inflammatory arthritis, sicca syndrome, myositis, polymyalgia rheumatica, and several other rare phenotypes. The CTLA-4 and PD-1/PD-L1 pathways have been linked to the pathophysiology of rheumatoid arthritis (RA). In this study, we particularly focused on the outcome of ICI treatment in patients with pre-existing RA.

Methods: We searched PubMed from 2014 to 2024 using the keywords “ICI, irAEs, rheumatoid arthritis, rheumatology”. We only included studies that involved patients with rheumatoid arthritis and we found a total of 23 studies. Data on RA disease activity and treatment regimens were collected, including the use of systemic steroids, DMARDs, and symptomatic treatments.

Results: We identified 1616 oncology patients with PAD who were given ICIs. The mean age of the participants ranged from 54 to 72. The most common cancer types were melanoma, NSCLC, and urinary tract carcinomas. 194 out of 1616 patients (12%) had rheumatoid arthritis diagnosis according to ACR/EULAR criteria. Among the reported ones, only 41.9% (95% CI 32.5%, 51.3%) of RA patients showed disease activity. Treatment for pre-existing RA varied, with 19% treated with only systemic steroids, 8% with steroids and DMARDs, 14% with only DMARDs, and 58% with only symptomatic treatment. 25.3% (95% CI 18.5%, 32.1%) of patients developed irAEs (colitis mostly), while 50% (95% CI 42.2%, 57.8%) had a flare of their pre-existing autoimmune diseases. The ICI discontinuation rate due to irAEs or flares was 15.9% (95% CI 8.9%, 22.8%). Only one patient’s death was thought to be due to irAEs (colitis); other deaths were attributed to progressive disease. De novo irAEs and flares were effectively managed using standard treatment protocols in almost all cases and did not prevent the patients from receiving clinical benefits.

Conclusion: Our research discovered that more than 70% of cancer patients with pre-existing autoimmune diseases experienced either autoimmune exacerbations or immune-related adverse events. Immunotherapy for cancer presents ongoing challenges in individuals with rheumatic diseases. Pre-existing autoimmunity does not serve as an absolute contraindication for ICI treatment. It is crucial to engage in a thorough discussion regarding individual expectations and available treatment options. There is very limited data on this topic, highlighting the need for further research to guide clinical decision-making.


Disclosures: B. Ibis: None; F. Bahar: None.

To cite this abstract in AMA style:

Ibis B, Bahar F. Can Immune Checkpoint Inhibitors Safely Combat Cancer in Patients with Rheumatoid Arthritis? [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/can-immune-checkpoint-inhibitors-safely-combat-cancer-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-immune-checkpoint-inhibitors-safely-combat-cancer-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology